|
| Status |
Public on Jan 27, 2020 |
| Title |
RNA-seq control (sgNT) and TLE3KO (sgTLE3) cells treated with 10 uM enzalutamide or vehicle |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
To investigate the transcriptional consequences of TLE3 loss in the presence/absence of AR inhibitor enzalutamide in prostate cancer cells, the transcriptomes of WT and TLE3KO cells treated with vehicle or enzalutamide (10 uM) were compared. .
|
| |
|
| Overall design |
WT and TLE3KO LNCaP cells treated with 10 uM enzalutamide or vehicle for 5 days (3 replicates)
|
| |
|
| Contributor(s) |
Palit S, Vis D, Lieftink C |
| Citation(s) |
31855178 |
| |
| Submission date |
Apr 24, 2019 |
| Last update date |
Jan 27, 2020 |
| Contact name |
Sander Palit |
| E-mail(s) |
s.palit@nki.nl
|
| Organization name |
Netherlands Cancer Institute
|
| Street address |
Plesmanlaan 121
|
| City |
Amsterdam |
| ZIP/Postal code |
1066 CX |
| Country |
Netherlands |
| |
|
| Platforms (1) |
| GPL16791 |
Illumina HiSeq 2500 (Homo sapiens) |
|
| Samples (12)
|
|
| Relations |
| BioProject |
PRJNA534447 |
| SRA |
SRP193707 |
Less...
More...